- Home
- NNE vs DNTH Comparison
NNE vs DNTH Comparison
Compare NNE & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNE
- DNTH
- Stock Information
- Founded
- NNE 2022
- DNTH 2015
- Country
- NNE United States
- DNTH United States
- Employees
- NNE N/A
- DNTH N/A
- Industry
- NNE
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- NNE
- DNTH Health Care
- Exchange
- NNE NYSE
- DNTH Nasdaq
- Market Cap
- NNE 718.5M
- DNTH 823.1M
- IPO Year
- NNE 2024
- DNTH N/A
- Fundamental
- Price
- NNE $19.56
- DNTH $27.86
- Analyst Decision
- NNE Strong Buy
- DNTH Strong Buy
- Analyst Count
- NNE 2
- DNTH 8
- Target Price
- NNE $44.50
- DNTH $45.14
- AVG Volume (30 Days)
- NNE 6.1M
- DNTH 211.1K
- Earning Date
- NNE 11-14-2024
- DNTH 11-07-2024
- Dividend Yield
- NNE N/A
- DNTH N/A
- EPS Growth
- NNE N/A
- DNTH N/A
- EPS
- NNE N/A
- DNTH N/A
- Revenue
- NNE N/A
- DNTH $4,118,000.00
- Revenue This Year
- NNE N/A
- DNTH $41.61
- Revenue Next Year
- NNE N/A
- DNTH N/A
- P/E Ratio
- NNE N/A
- DNTH N/A
- Revenue Growth
- NNE N/A
- DNTH 8.57
- 52 Week Low
- NNE $3.25
- DNTH $6.58
- 52 Week High
- NNE $37.51
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- NNE N/A
- DNTH 50.71
- Support Level
- NNE N/A
- DNTH $27.17
- Resistance Level
- NNE N/A
- DNTH $28.32
- Average True Range (ATR)
- NNE 0.00
- DNTH 1.37
- MACD
- NNE 0.00
- DNTH 0.01
- Stochastic Oscillator
- NNE 0.00
- DNTH 63.42
About NNE NANO NUCLEAR ENERGY INC
Nano Nuclear Energy Inc is an early-stage nuclear energy company developing smaller, cheaper, and safer advanced portable clean energy solutions. It is focused on four business lines as part of development: Micro Nuclear Reactor Business is developing the next-generation nuclear microreactors, in particular ZEUS, a solid core battery reactor, and ODIN, a low-pressure salt coolant reactor. Fuel Fabrication Business, Fuel Transportation Business and Nuclear Consultation Services.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.